IL6 and bacterial infectious disease: Tocilizumab, an anti-IL-6 medication, and baricitinib, a JAK kinase inhibitor, are used in patients with rapidly progressing COVID-19.81,82 Despite the clinical improvement these drugs can provide, they also increase the risk of bacterial infection, including HAIs.